Alveolar Rhabdomyosarcoma Treatment Market Key Players, Trends, Emerging Growth Factors and Regional Forecasts to 2026, Analysis and In-depth Research on Market Size
Alveolar
rhabdomyosarcoma (ARMS) is a type of soft tissue sarcoma that
originates from the connective tissues of the body such as bone,
muscle, cartilage, and ligaments. According to the survey by
Children’s Oncology Group, 2011, alveolar rhabdomyosarcoma makes up
about 25-40% of RMS. ARMS is mostly detected in adolescents and often
occurs on the arms, legs, chest, and stomach. The exact cause of
alveolar rhabdomyosarcoma is unknown, however it is associated with
other conditions such as Neurofibromatosis type 1, Beckwith-Wiedemann
syndrome, Li-Fraumeni syndrome, Cardio-facio-cutaneous syndrome, and
Costello syndrome. The methods for diagnosis of ARMS include
examination such as X-ray imaging, CT scan, MRI, bone scan,
ultrasound, PET scan, and a biopsy, in order to plan a suitable
treatment for the condition. ARMS is a type of high-grade tumor
meaning it cells are characterized by rapid growth and faster
progression.
Alveolar
Rhabdomyosarcoma Treatment Market: Regional Dynamics
Regional
segmentation of the global alveolar rhabdomyosarcoma treatment market
by Coherent Market Insights comprises North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa. North America is
expected to hold a dominant position in the global alveolar
rhabdomyosarcoma treatment market over the forecast period, owing to
rising number of initiatives undertaken by organizations in the
region to develop potential therapies, increasing research and
development, and adoption of advanced radiation therapies.
Organizations in the region have initiated the first molecular
targeted drug in a clinical trial in 2011, for childhood muscle
cancer at the Doernbecher Children's Hospital and Children Oncology
Group (COG) sites. Also, St. Baldrick’s Foundation works in
collaboration with pediatric oncologists and funds supportive cancer
research to develop promising research to positively impact treatment
of children with cancer. Moreover, other organization such as the
National Cancer Institute, Scott Carter Foundation, Alex's Lemonade
Stand Foundation, and the Hyundai Hope on Wheels Program have funded
various studies, in order to explore highly potential therapeutic
options. The alveolar rhabdomyosarcoma treatment market in Asia
Pacific is expected to witness high growth, owing to rising awareness
of the disease in the regions supported by advancements in the
medical settings to adopt novel therapies.
Alveolar
Rhabdomyosarcoma Treatment Market: Competitive Analysis
Key players
operating in the global alveolar rhabdomyosarcoma treatment market
include Eli Lilly and Company, GlaxoSmithKline Plc., Boehringer
Ingelheim GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Oasmia
Pharmaceutical, Celgene Corporation, Pfizer, Inc., and Johnson &
Johnson Services, Inc.
Inquire Here
Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1552
Alveolar
Rhabdomyosarcoma Treatment Market: Market Taxonomy
On the basis of
therapy type, the global alveolar rhabdomyosarcoma treatment market
is segmented into:
Chemotherapy
Radiation
Therapy
Combination
Therapy
On the basis of
end user, the global alveolar rhabdomyosarcoma treatment market is
segmented into:
Hospitals
Specialty
Clinics
Ambulatory
Surgical Centers
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment